Skip to main content
. 2014 Aug 11;7:1415–1422. doi: 10.2147/OTT.S64559

Figure 6.

Figure 6

(A) The PFS of the one-third of patients, with and without bevacizumab, in the low serum LDH group; (B) the PFS of the one-third of patients, with and without bevacizumab, in the middle serum LDH group; (C) the PFS of the one-third of patients, with and without bevacizumab, in the high serum LDH group.

Abbreviations: LDH, lactate dehydrogenase; PFS, progression-free survival.